Abstract
AKT/PKB (Protein Kinase B) are central proteins mediating signals from receptor tyrosine kinases and phosphatidylinositol 3-kinase. AKT kinases are involved in a number of important cellular processes including cell proliferation and survival, cell size in response to nutrient availability, tumor invasion/metastasis, and angiogenesis. Various components of the AKT signaling pathway are encoded by tumor suppressor genes and oncogenes whose loss or activation, respectively, plays an important role in tumorigenesis. The growing body of evidence connecting deregulated AKT signaling with sporadic human cancers and inherited cancer predisposition syndromes is discussed. We also highlight new findings regarding the involvement of activating mutations of AKT1, AKT2, and AKT3 in somatic overgrowth disorders: Proteus syndrome, hypoglycemia with hypertrophy, and hemimegalencephaly, respectively. In addition, we review recent literature documenting the various ways the AKT signaling pathway is activated in human cancers and consequences for molecularly targeted therapies.
Keywords: AKT/PKB kinases, hemimegalencephaly, human malignancy, hypoglycemia, oncogenes, proteus syndrome, targeted therapies, tumor suppressor genes
Current Cancer Drug Targets
Title:Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Volume: 13 Issue: 3
Author(s): Mitchell Cheung and Joseph R. Testa
Affiliation:
Keywords: AKT/PKB kinases, hemimegalencephaly, human malignancy, hypoglycemia, oncogenes, proteus syndrome, targeted therapies, tumor suppressor genes
Abstract: AKT/PKB (Protein Kinase B) are central proteins mediating signals from receptor tyrosine kinases and phosphatidylinositol 3-kinase. AKT kinases are involved in a number of important cellular processes including cell proliferation and survival, cell size in response to nutrient availability, tumor invasion/metastasis, and angiogenesis. Various components of the AKT signaling pathway are encoded by tumor suppressor genes and oncogenes whose loss or activation, respectively, plays an important role in tumorigenesis. The growing body of evidence connecting deregulated AKT signaling with sporadic human cancers and inherited cancer predisposition syndromes is discussed. We also highlight new findings regarding the involvement of activating mutations of AKT1, AKT2, and AKT3 in somatic overgrowth disorders: Proteus syndrome, hypoglycemia with hypertrophy, and hemimegalencephaly, respectively. In addition, we review recent literature documenting the various ways the AKT signaling pathway is activated in human cancers and consequences for molecularly targeted therapies.
Export Options
About this article
Cite this article as:
Cheung Mitchell and R. Testa Joseph, Diverse Mechanisms of AKT Pathway Activation in Human Malignancy, Current Cancer Drug Targets 2013; 13(3) . https://dx.doi.org/10.2174/1568009611313030002
DOI https://dx.doi.org/10.2174/1568009611313030002 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Patent Selections:
Recent Patents on Food, Nutrition & Agriculture Metal Oxide Nanomaterials in Nanomedicine: Applications in Photodynamic Therapy and Potential Toxicity
Current Topics in Medicinal Chemistry Enhanced Oral Bioavailability of Etodolac by the Liquisolid Compact Technique: Optimisation, In-Vitro and In-Vivo Evaluation
Current Drug Delivery Tandem Multicomponent Reactions Toward the Design and Synthesis of Novel Antibacterial and Cytotoxic Motifs
Current Medicinal Chemistry The Role of Cytochrome P450 in Cytotoxic Bioactivation: Future Therapeutic Directions
Current Cancer Drug Targets Modulation of the TRPV1 Channel: Current Clinical Trials and Recent Patents with Focus on Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Blind Snipers: Relevant Off Target Effects of Non-chemotherapeutic Agents in Oncology: Review of the Literature
Reviews on Recent Clinical Trials Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Smart Synthetic Polymer Nanocarriers for Controlled and Site-Specific Drug Delivery
Current Topics in Medicinal Chemistry The Use of SIFT-MS in Profiling the Faecal Volatile Metabolome in Horses with Colic: A Pilot Study
Current Analytical Chemistry The Novel Synthesized Pyridazinone Derivates had the Antiproliferative and Apoptotic Effects in SHSY5Y and HEP3B Cancer Cell Line
Letters in Organic Chemistry Expression of Fucosyltransferases Contributes to Melanoma Invasive Phenotype
Medicinal Chemistry Recent Advances in the Synthesis and Applications of Multimodal Gold-Iron Nanoparticles
Current Medicinal Chemistry Polysaccharide Based Formulations for Mucosal Drug Delivery: A Review
Current Pharmaceutical Design Gemcitabine: A Critical Nucleoside for Cancer Therapy
Current Medicinal Chemistry Targeting Metallothionein for Prognosis and Treatment of Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery Linking New Paradigms in Protein Chemistry to Reversible Membrane-Protein Interactions
Current Protein & Peptide Science